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Abstract 
Background: Dynein is a cytoskeletal molecular motor protein that transports cellular cargoes along microtubules. 
Biomimetic synthetic peptides designed to bind dynein have been shown to acquire dynamic properties such as 
cell accumulation and active intra‑ and inter‑cellular motion through cell‑to‑cell contacts and projections to distant 
cells. On the basis of these properties dynein‑binding peptides could be used to functionalize nanoparticles for drug 
delivery applications.
Results: Here, we show that gold nanoparticles modified with dynein‑binding delivery sequences become mobile, 
powered by molecular motor proteins. Modified nanoparticles showed dynamic properties, such as travelling 
the cytosol, crossing intracellular barriers and shuttling the nuclear membrane. Furthermore, nanoparticles were 
transported from one cell to another through cell‑to‑cell contacts and quickly spread to distant cells through cell 
projections.
Conclusions: The capacity of these motor‑bound nanoparticles to spread to many cells and increasing cellular reten‑
tion, thus avoiding losses and allowing lower dosage, could make them candidate carriers for drug delivery.
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Background
Motor proteins are biological molecules that transform 
chemical energy into mechanical force at the nanoscale 
[1]. These molecular motors can be integrated into 
hybrid biological and synthetic systems to functionalize 
nanoparticles (NPs) for biotechnological applications [2].
Engineered nanocomposites have been built in order to 
overcome intracellular barriers and to mimic how intra-
cellular pathogens such as viruses transfer their genetic 
material into the cells [3]. Several design strategies 
have been tested in order to increase NPs translocation 
through cellular membranes, thereby enhancing transfec-
tion efficiency. Ligands conjugated to the surface of engi-
neered NPs such as sugars [4] can influence the mode of 
cellular internalization [5]. Nevertheless, NPs of the same 
composition may use alternative mechanisms for cell 
entry in different cell types [6].
Once inside the cell and given the crowded gel-like com-
position of the cytoplasm, the movement of organelles and 
macromolecules is restricted [7]. Furthermore, eukaryotic 
cells are compartmentalized by endomembrane systems 
and cytoskeleton filaments of actin, and microtubules are 
used as tracks for transport. This transport relies on energy-
dependent molecular motors that are necessary for com-
munication between compartments. To move in a crowded 
cellular environment poses problems to NP displacement 
and thus, vector design strategies have included different 
mediators of intracellular trafficking in order to facilitate 
this transport, some of them considering the cytoskeleton 
[8–10]. In fact, viruses, strictly depending on their capac-
ity to invade and control the intracellular environment, 
have developed specific strategies to bind microtubule 
motors to facilitate their transport along these filaments to 
reach the perinuclear area and initiate replication [11–15]. 
Microtubule motor binding is crucial for the replication 
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and dissemination of several viruses. In-depth knowledge 
of some of these strategies of virus-cell interaction can be 
exploited to design virus-free delivery systems [16–18].
We used a biomimetic approach based on selected 
peptide sequences from viral proteins known to bind 
dynein. Dynein is a microtubule motor acting as a hub 
protein within the microtubule-motor complex, which 
exerts several functions related to movement in mam-
malian cells. This protein is responsible for cargo trans-
port within cells, up to organelle-size cargoes [19]. It is 
also responsible of nuclear positioning within the cell and 
has several functions in mitosis [20–22]. Onset of mitosis 
is marked by centrosome migration for the mitotic spin-
dle formation that requires dynein. Also, dynein action 
on microtubules leads to nuclear envelope breakdown at 
early mitosis and to its reorganization after the end of cell 
division [23–25]. The loss of nuclear compartmentaliza-
tion induced by the breakdown of the nuclear envelope 
is characterized by increased permeability together with 
the initiation of the nuclear pore disassembly [26]. Thus, 
dynein has the potential capability to drive nuclear enve-
lope disassembly and permeate this layer, that is, a par-
ticularly important property since the nuclear membrane 
is the “last barrier” for gene delivery in non-dividing cells.
Dynein exists within a complex of several subunits and 
adapters [27] and contains two heavy chains and several 
intermediate, light intermediate and light chains [28, 29]. 
One of the light chains is DYNLL1, a highly evolutionar-
ily conserved protein that is hijacked by a number of viral 
proteins for transport [30]. The high affinity interaction 
of viral proteins with DYNLL1 [31] and its ability to form 
long half-live molecular complexes make this molecule 
especially appropriate to build supramolecular structures 
[32]. Then, we used peptide sequences from viral proteins 
interacting with DYNLL1 to modify NPs based in the 
hypothesis that this modification could confer dynamic 
properties to the NPs, enhancing their motility and dis-
persion in the intracellular environment.
In the present work, gold NPs (Au NPs) have been 
modified with short peptide sequences taken from viral 
proteins that bind dynein. We found a highly active intra-
cellular trafficking and cellular uptake of those modified 
carriers in several cell lines. Dynein-binding peptides 
(DBPs) modified NPs were motile throughout the cyto-
sol and travelled from cell-to-cell favoring the propaga-
tion of this uptake. By this active cellular transport, NPs 
acquired the property to shuttle the nuclear membrane in 
non-dividing cells.
Results
Dynein‑binding peptides modified nanoparticles design
Here, we report the production of water-soluble and sta-
ble Au NPs modified with DBPs as an efficient approach 
for cargo delivery. Au NPs of different sizes have been 
widely used because of lack of apparent toxicity, and 
easy elimination by renal clearance in case NPs are small 
enough (sizes bellow 10 nm) [33, 34]. Coating NPs with 
organic molecules and/or macromolecules has been typi-
cally employed in order to improve NP stability and pre-
vent aggregation [33], as for instance Au NPs coated with 
tiopronin (Au@tiopronin) [35]. Tiopronin is a thiolated 
derivative of the amino acid glycine. Au@tiopronin were 
prepared using the procedure originally reported by 
Murray et al. [34]. These NPs consist of small (typically, 
core diameter < 3  nm) Au NPs stabilized with the non-
natural aminoacid tiopronin (N-2-mercaptopropionylgly-
cine), which has a free terminal carboxyl group, allowing 
to functionalize Au@tiopronin with aminated molecules 
[35], such as the DBPs sequences, by carbodiimide 
chemistry, cf. Figure  1. The reaction was executed in a 
methanolic/acetic acid mixture, dissolving  HAuCl4 and 
tiopronin to give a stable solution. The addition of  NaBH4 
as reducing agent provided a dark solution by reduction 
of the gold salt and formation of the NPs. Acidic condi-
tions are very important to guarantee the protonation of 
tiopronin carboxylic groups, and provide an efficient and 
dense self-assembled monolayer of tiopronin onto the 
NPs. The obtained NPs were colloidally stable in aque-
ous solution. The excess of tiopronin and salts was elimi-
nated by dialysis. The purified NPs were characterized by 
TEM and UV/Vis, cf. Additional file  1: Figure S1. TEM 
images showed a mean diameter of 2.8  nm for the Au 
core (Fig. 1a). The UV/Vis absorption spectra showed an 
almost non-detectable surface plasmon band consistent 
with the small NP size of the NPs, cf., Additional file  1: 
Figure S1.
Using the reactivity of the tiopronin carboxylic group, 
further functionalization with aminated molecules was 
carried out using a procedure previously described [35] 
(Fig. 1): 1) Aminated poly(ethylene glycol) (PEG) deriva-
tive  (CH3O-PEG-NH2); 2) different peptide sequences 
(Table 1) and 3) fluorescent dye TAMRA-CAD (i.e., tetra-
methylrhodamine 5-carboxamide cadaverine), which was 
used to optimize carbodiimide coupling conditions. PEG 
molecules were selected to avoid unspecific interactions. 
A dense layer of PEG confers anti-fouling properties to 
nanomaterials, thereby increasing their colloidal stability 
in aqueous solution and reducing unspecific interactions 
with other molecules such as plasma proteins [36–38].
The selected dynein-binding peptide (DBP) sequences 
were synthetic peptides spanning the dynein-binding 
domain of different proteins, cf. Table  1. We selected 
three peptides: DynPro (dynein-propelled) derived from 
the product of the E183L gene of the African swine fever 
virus (p54) [11, 31]; ShortPro, a shorter sequence of 
the same protein based on the critical amino acids for 
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dynein-binding; and TransRb derived from the Rabies 
virus P protein [39]. As a negative control, a non-dynein-
binding amino acid sequence (IntCt) was selected. To 
guarantee the proper presentation of the peptides and 
minimize steric hindrance due to a dense packaging of 
molecules on the NP surface, a tetra- or octa-glycine tail 
was added to DynPro and IntCt, or ShortPro and Tran-
sRb, respectively. After the glycine-tail, a lysine residue 
was added. Primary amine moieties of the lysine residues 
were used for fluorescent labeling with 5-carboxytetra-
methylrhodamine (TAMRA). Finally, an octa-arginine 
tail was added to these peptides’ end, including to the 
control peptide IntCt, to increase the positive charge 
of the peptides, thereby enhancing cellular uptake, cf. 
Table 1.
NPs´carboxyl groups and primary amines of the 
selected ligands (PEG derivative, TAMRA-CAD and 
DBPs) were crosslinked with the water-soluble carbodi-
imide N-[3-(dimethylamino)propyl]-N’-ethylcarbodiim-
ide hydro-chloride (EDC). N-hydroxysulfosuccinimide 
(sulfo-NHS) was also included in the reaction mixture 
to improve the efficiency of the carbodiimide-medi-
ated amide-forming reaction by producing hydrolysis-
resistant active ester reaction intermediates (Fig. 1). The 
resultant library of NPs was analyzed by ζ-potential, UV/
Vis and fluorescence spectroscopy, probing that the mol-
ecules were incorporated to the NPs and the absence of 
aggregation after peptide coupling, cf. Additional file  1: 
Figure S3.
Modified nanoparticles internalization
NPs covalently functionalized with TAMRA-labeled pep-
tides were visualized by live-cell imaging, which allowed 
tracking of their movement at the intracellular level. The 
cellular uptake of Au@tiopronin NPs modified with DBPs 
(Au@DBPs; Fig.  2b, e–h) was significantly more effi-
cient compared to those functionalized with the control 
Fig. 1 a Scheme of NPs synthesis (Au@tiopronin) and functionalization with dynein‑binding peptides (DBP) and PEG. b TEM image of Au@tio‑
pronin. Scale bar: 20 nm
Table 1 Alias, sequence and molecular weight (MW) of the 
peptides used to surface modify the Au@tiopronin NPs
Alias Amino acid sequence MW (Da)
DynPro GGGGK(TAMRA)‑HPAEPGSTVTTQNTASQTMS‑
RRRRRRRR
4063.5
ShortPro GGGGGGGGK(TAMRA)‑YTTQNTASQTMS‑RRRRRRRR 3578.9
TrasnRb GGGGGGGGK(TAMRA)‑FPNPSGRSSEDKSTQTAG‑
RRRRRRRR
4112.5
IntCt GGGGK(TAMRA)‑SLVSSDESVLHGSHESGEHV‑
RRRRRRRR
4110.5
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peptide IntCt (i.e., Au@IntCt) in Vero cells (p < 0.001; 
Fig.  2c). Similar results were obtained with other cell 
lines, such as the neuroblastoma cell line SK-N-MC, the 
epithelial cell line MDCK, HeLa (derived from a human 
epithelial carcinoma) and HEK293T cell line (human kid-
ney embryonic transformed cell line; Fig.  2d–h). Time-
dependent intracellular accumulation was observed from 
20 to 120  min with Au@DBPs and Au@IntCt (Fig.  2i). 
Concentration of Au@DBPs increased until 180  min, 
remaining stable thereafter and visible up to 12  h. 
Quantitative fluorescence percentages were also analyzed 
by flow cytometry with increasing doses of NPs (Fig. 2j). 
Overall, the cellular distribution among the functional-
ized Au@DBPs was similar (Fig.  3a–c). Au@DBPs were 
rapidly internalized and distributed widely within the cell 
and throughout the culture. While NPs stability in cell 
culture media was clearly observed, PEG modification did 
not result in significant modification of Au@DBPs uptake 
in cells incubated with 0.2 mg/ml NPs (ca. 1.5 μM NPs) 
for several times 1, 2 or 3 h (Additional file 1: Figure S4).
Fig. 2 Cellular distribution of NPs. a, d Mean fluorescence intensity (MFI) of intracellular Au@tiopronin modified with DynPro (Au@DynPro) or 
IntCt (Au@IntCt) after 1 h incubation with Vero cells (a) and other cell lines (d). Differences in MFI between Au@DBPs and Au@IntCt (control) were 
statistically significant p value of 0.001 (α = 0.05). In contrast, differences among Au@DBPs were not significant with a p value of 0.3 (α = 0.05; not 
shown). b Representative confocal images of Vero cells incubated with Au@DynPro or c Au@IntCt. e–h Representative confocal images of SK‑N‑MC 
(e), HeLa (f), 293T (g) and MDCK cells incubated with Au@DynPro. Scale bar: 10 µm. i Time‑dependent accumulation of Au@DynPro at several time 
points between 20 and 120 min, as indicated. j Fluorescence intensity percentages at increasing doses of Au@DynPro quantified by flow cytometry
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Nanoparticles dynamic properties
Time-lapse videomicroscopy unraveled Au@DBP bidi-
rectional movement across the cytosol and a continuous 
flow to cell projections reaching neighboring or distant 
cells (Fig.  3a-c and Additional file  2: Movie 1). Also, 
we observed bidirectional movement towards the cell 
periphery, to cell projections and intercellular cell-to-cell 
transport. No differences were found among Au@DBPs 
in terms of distribution and dynamic properties (Fig. 3a–
c, Additional file 2: Movies 1, Additional file 3: Movies 2). 
Au@DBPs exhibited high-speed mobility (median speed 
0.25 ± 0.2  µm/s). This movement followed linear trajec-
tories allowing progression of Au@DBPs (Fig.  3d, e). In 
contrast, the movement of NPs functionalized with con-
trol peptide (Au@IntCt) was non-progressive, non-linear 
(Fig. 3f ).
Microtubule‑dependent transport of nanoparticles
Linear movement of Au@DBPs, with occasional pauses 
and alternating directions, suggested that this was a 
Fig. 3 Representative confocal images at low magnification of a Vero cells with Au@DynPro b HEK293T cells with Au@ShortPro and c MDCK cells 
with Au@TransRb. Representative images showed similar NP dispersion throughout the culture and cell‑to‑cell transfer of Au@DynPro through 
short (b) or long (c) projections. d, e Representative time‑lapse images of the linear progression of Au@DBP inside the cell and the resulting trajec‑
tories (circles). f Comparison with the non‑linear movement obtained with control NPs Au@IntCt. Scale bar: 5 µm
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microtubule-dependent transport. During the first min-
utes after incubation, Au@DBPs were rapidly internal-
ized, moved and accumulated near the nucleus at the 
microtubule-organizing center (MTOC) (Fig.  4a). This 
preferential localization of Au@DBPs at the MTOC 
was found in non-polarized cells (Fig.  4b). Conversely, 
in polarized cells, movement was directed to the cell 
periphery and to cell projections (Fig. 4c). Linear move-
ment of Au@DBPs was bidirectional, reached the cell 
periphery and projections being transported from one 
Fig. 4 a Accumulation of Au@DynPro at the MTOC near the nucleus (N). b Progression of Au@DynPro towards the MTOC, or c nucleus and projec‑
tions (arrows) in GFP‑tubulin transfected cells. d–i Au@DynPro´s mobility was sensitive to microtubule‑depolimerizing drugs. d, g Widespread cellu‑
lar distribution of Au@DynPro before depolymerizing drug treatment, e Au@DynPro transport blockade and accumulation after 1 h drug incubation 
with 2.5 µM Nocodazole, and f mobility and dispersion recovery after washing. g Vero cells treated with 10 µM Au@DynPro and then h incubated 
for 1 h with 0.1 µM actin depolymerizing‑drug LatrunculinA. This drug produced cell shrinkage because of actin cytoskeleton collapse that was not 
recovered after washing (i). However, Au@DynPro transport was still preserved within cells and projections. Scale bar: 10 µm
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cell to another. These characteristics were found for all 
Au@DBPs tested.
Au@DBP dispersed distribution, movement and spread 
(Fig.  4d) was reversibly stopped with the microtubule 
depolymerizing agent Nocodazole (Fig. 4e). After wash-
ing and media replacement, movement and dispersion 
of Au@DBPs in the culture were recovered (Fig.  4f ). In 
contrast, drugs that depolymerize the actin cytoskel-
eton, such as Latrunculin A, did not stop the motion of 
the Au@DBP between cells through projections, even 
under conditions of cell collapse after actin cytoskeleton 
depolimerization (Fig.  4g–i). This effect was not revers-
ible by washing and media replacement as expected.
Efficient transport of Au@DBP across the nuclear 
membrane
Au@DBPs crossed the nuclear envelope and travelled the 
nuclear compartment (Fig.  5). This property was found 
for all the different Au@DBPs tested but not for the con-
trol Au@IntCt (Fig.  2c). Au@DBPs produced a visible 
imprint of their movement along the nucleus that was 
physically evident using bright field microscopy as lin-
ear protrusions as Au@DBPs moved through the nuclear 
area and the nucleolus (Fig. 5a, b, g).
Au@DBPs travelled across the nuclear envelope and 
the nuclear lamina, as shown in GFP-laminB receptor 
(Fig.  5c) and GFP-laminB1 transfected cells (Fig.  5d, e). 
In fact, Au@DBPs produced invaginations of the nuclear 
envelope at multiple sites (Figure 5c–e).
In the nucleolus, peptides colocalized with GFP-B23 
nucleolin as they crossed the nucleolus, without affecting 
the morphology of this structure (Fig. 5f ). Similarly, Au@
DBPs entered nucleolus (Fig. 5g).
It is important to note that cell viability and cell pro-
liferation were unaffected with any Au@DBP formulation 
(Additional file 1: Figure S5).
Discussion
Molecular motors have previously allowed developing 
nanoscale transport systems powered by biomolecular 
motors or molecular shuttles [7]. Peptides binding to a 
cellular protein that is highly evolutionarily conserved 
(DYNLL1) [19] and a molecular hub building long-life 
molecular complexes in cells, made this transport very 
efficient in a number of cell lines tested, including mam-
malian cells and some of non-mammalian origin [21, 27, 
40].
Here, the dynamic properties of DBPs were successfully 
translated into Au NPs (i.e., Au@DBPs), which may be 
highly useful in the drug delivery area. These results are 
in agreement with previous reports that employed soft 
carriers, such as microspheres [41] or liposomes [42], 
functionalized with dynein light chain 8 (LC8) peptide 
binding motifs. Similarly, in the present work, we selected 
peptides able to bind a dynein chain with very high affin-
ity [31], which were linked to hard Au@tiopronin NPs. In 
our study, non-significant differences regarding dynamic 
properties between Au@DBPs and “bare” DBPs were 
observed. Probably, this fact occurs due to the small size 
of our Au NPs, limiting the interaction of one dynein 
with one NP. Moreover, a previous theoretical work sug-
gested that motor protein binding molecules attached to 
solid carriers work collectively rather than cooperatively 
[43].
NPs are small particles (from a few to 200 nm in diam-
eter) especially useful for delivery as can be aerosolized 
[44], can be made highly biocompatible, allow site spe-
cific targeting to a specific cell population, permit con-
trolled drug release and can be designed to biodegrade in 
an acceptable time span [35, 45]. The stability found for 
Au@DBPs and long times of persistence inside the cul-
tured cells, make them suitable candidates for drug deliv-
ery. The Au@DBPs ability for spreading to neighboring 
cells remaining intracellular would improve efficacy and 
optimize dosage for compounds to be delivered.
Dynein has a central role in the formation of the mitotic 
spindle during mitosis and interacts dynamically with the 
nuclear envelope directing assembly and reassembly of 
nuclear lamins. The penetration capacity of Au@DBPs 
could rely on the ability of dynein to interact dynamically 
with the nuclear envelope and thus direct the disassem-
bly of nuclear lamins as it occurs at early stages of mitosis 
[23, 25]. Other cell delivery mechanisms allow entering 
the nucleus efficiently only in dividing cells, because of 
nuclear envelope rearrangements naturally occurring 
at prometaphase. In contrast, Au@DBPs are virus-free 
delivery vehicles that elicited nuclear envelope reorgani-
zation also in non-dividing cells. Hence, Au@DBPs were 
able to take advantage of these properties, move in the 
crowded cellular environment and change the permeabil-
ity of the nucleus compartment.
Targeting of drugs and NPs to tumors poses particu-
lar difficulties in delivery; drugs only penetrate few cells 
around blood vessels [46, 47]. This problem is particularly 
found in solid tumors, which are poorly perfused because 
blood vessels and lymphatics are usually dysfunctional. 
The leakiness of tumor vessels impairs enhanced per-
meability and retention effect of compounds delivered 
[48]. The capacity of Au@DBPs to be transferred from 
one cell to another could boost spreading of therapeutic 
NPs reaching neighboring cells. This would allow optimal 
dosage, increasing therapeutic effect and minimizing side 
effects.
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Fig. 5 a, b Nuclear penetration capacity of Au@DynPro (n: nucleus). c–e Nuclear envelope appeared discontinuous as Au@DynPro shuttle the 
nucleus in Vero cells transfected with GFP‑laminB receptor (c) and GFP‑laminB1 (d, e) as shown in equatorial optical sections. Sample images show 
NPs entering the nucleus and nuclear lamina folding at sites of NPs entry. f Peptides shuttle the nucleus in Vero cells transfected with GFPB23 
nucleolin (g) Au@DynPro in their way across the nucleus with visible imprints of their paths (b, arrow). Scale bar: 5 μm
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Conclusions
We have shown dynein-motor powered NP motil-
ity in the crowded cellular environment and across the 
nuclear envelope. The dynamic properties of these Au@
DBPs made them especially appropriate to load com-
pounds and achieve the desired requirements of intracel-
lular delivery to all compartments. Moreover, the quick 
spreading of these functionalized NPs between cells, 
remaining intracellular, reduces exposure to the extra-
cellular environment minimizing eventual loses. These 
characteristics, together with their intracellular accumu-
lation capacity would in turn allow reductions on admin-
istration doses of a given drug or therapy because of its 
better biodisponibility in a handful of applications.
Methods
Peptides and cell lines
Peptide sequences spanned the DYNLL1 binding domain 
of viral proteins (Table  1), that is, African swine fever 
virus p54 (DynPro) and a shorter sequence including 
critical amino acids for binding (ShortPro), Rabies virus 
P protein (TransRb), and control non-dynein-binding 
amino acid sequence (IntCt). An octa-arginine tail was 
added to all these peptides, which were also labeled 
with TAMRA. Peptides were synthesized and purified 
by HPLC over 95% of purity by Genecust. The following 
cell lines were tested: Vero kidney epithelial cells (ATCC 
CCL-81), Madin-Darby Canine Kidney Epithelial Cells 
(MDCK; ATCC CCL-34), Human embryonic kidney cells 
transformed with adenovirus 5 (HEK293T/17; ATCC 
CRL-11268), and Epidermal cancer cells (HeLa; CCL-
2). Cells were cultured in DMEM with FBS from Lonza. 
SK-N-MC human neuroblastoma cells were cultured in 
EMEM with pyruvate (ATCC HTB-10). These mamma-
lian cells were incubated in sterile 35-mm culture dishes 
with 10 µM peptides, or 1.5 µM NPs, in a  CO2 incubator 
at 37 °C for 1 h and then imaged.
Chemicals for nanoparticle synthesis
All the chemicals were of reagent grade and were used 
without further purification. Hydrogen tetrachloroaure-
ate (III) trihydrate (99.9%), (N-(3-dimethylaminopropyl)-
N´-ethylcarbodiimide hydrochloride, 
Tris(hydroxymethyl) aminomethane (TRIS, > 98.8%) and 
2-[N-morpholino] ethanesulfonic acid (99.5%) were pur-
chased from Sigma-Aldrich; N-(2-mercaptopropionyl) 
glycine (> 98%) and N-hydroxysulfosuccinimide (> 97%) 
were purchased from Fluka and  NaBH4 (98%) from 
Lancaster. Dynein binding peptides (DBPs, i.e. DynPro, 
ShortPro and TransRb) and the control peptide (IntCt) 
were purchased from Genecust; α-methoxy-ω-amino 
polyethylene glycol  (CH3O-PEG-NH2, 750  Da) was 
obtained from Rapp-Polymere. Tetramethylrhodamine 
5–carboxamide cadaverine (TAMRA-CAD) was pur-
chase from Anaspec. Phosphate buffer saline (PBS) was 
obtained from Lonza. House distilled water was further 
purified using a Milli-Q reagent grade water system (Mil-
lipore). Buffers were prepared according to standard lab-
oratory procedure. Other chemicals were reagent grade 
and used as received.
Nanoparticle synthesis and characterization
Characterization
UV–Vis spectra were carried out with Varian Cary 50 
spectrophotometer. Florescence spectra were carried 
out with a LS-55 Fluorescence Spectrometer. ζ-potential 
measurements were done using a ZetaPALS analyser 
from Brookhaven. All spectra were collected in MilliQ 
water; for ζ-potential characterization the aqueous solu-
tion was adjusted to 1 mM KCl. For TEM examinations, 
a single drop (5 µl) of the aqueous solution (0.1 mg ml−1) 
of the Au NPs was placed onto a copper grid coated with 
a carbon film. The grid was left to dry in air for several 
hours at room temperature. TEM analysis was carried 
out on a Tecnai 20 FEI microscope operated at 200  kV. 
Particle size distribution of the Au NPs was evaluated 
from several micrographs using a program for image pro-
cessing and analysis (ImageJ).
Au@tiopronin
Hydrogen tetrachloroaureate(III) trihydrate (0.15  g, 
0.4  mmol) and N-(2-mercaptopropionyl) glycine (tio-
pronin; 0.19  g, 1.2  mmol) were codissolved in 20  ml of 
6:1 methanol/acetic acid, giving a ruby red solution. 
 NaBH4 (0.30  g, 8.0  mmol) in 7.5  ml of  H2O was added 
with rapid stirring. The black suspension that was formed 
was stirred for an additional 30 min after cooling, and the 
solvent was then removed under vacuum at 40  °C. The 
crude Au@tiopronin was completely insoluble in metha-
nol but quite soluble in water. It was purified by dialysis, 
in which the pH of 130 mg of crude product dissolved in 
20 ml of water was adjusted to 1 by dropwise addition of 
concentrated HCl. This solution was loaded into 15  cm 
segments of seamless cellulose ester dialysis membrane 
(Sigma, MWCO 10 kDa), placed in 4  l beakers of water, 
and stirred slowly, recharging with fresh water approxi-
mately every 10 h over the course of 72 h. The dark blue 
Au@tiopronin solutions were collected from the dialysis 
tubes and were lyophilized. Yield: 96 mg.
Au@peptides/TAMRA‑CAD/PEG
N-(3-Dimethylaminopropyl) -N´-ethylcarbodiimide 
hydro-chloride (EDC; 1 mg, 5 µmol) and N-hydroxysul-
fosuccinimide (sulfo NHS; 3 mg, 13.5 µmol) were added 
to 1  ml of Au@tiopronin (1  mg) in 2-[N-morpholino] 
ethanesulfonic acid (MES) (50 mM, pH 6.5). NPs were left 
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to react with EDC (carbodiimide activation) over 30 min 
at 37  °C under mild stirring conditions. NPs were then 
purified of excess EDC and sulfo NHS) over a PD-10 col-
umn (GE Healthcare). The peptide DynPro (27.5  nmol) 
or ShortPro (27.5  nmol) or TransRb (27.5  nmol) or 
IntCt3 (27.5  nmol) or TAMRA-CAD (55  nmol) were 
added and the mixture was stirred over 1 h at room tem-
perature before the addition of  CH3O-PEG-NH2 (750 Da; 
2.6 µmol) for coupling to remaining activated carboxylic 
groups; then samples were left under mild stirring con-
ditions at 4 °C overnight. Then, this solution was loaded 
into centrifugal filters (Amicon Ultra-0.5  ml, MWCO 
10  kDa) for three consecutive steps of purification of 
potentially uncoupled peptide, TAMRA or PEG, and con-
centration of the mixture prior to suspension in water. 
For preventing the possible absorption (non-covalently 
attached to the NPs) of TAMRA or any of the peptides, 
samples (0.5 ml at 2 mg mL−1) were loaded into ca. 1 cm 
segments of seamless cellulose ester dialysis membrane 
(Sigma, MWCO 10 kDa), placed in 1 l beakers of a solu-
tion 1  M NaCl in MilliQ water, and stirred slowly over 
the course of 72 h, recharging with fresh saline solution 
approximately every 10  h. Then, samples were desalted 
over a PD-10 column, concentrated with centrifugal fil-
ters (Amicon Ultra-0.5 ml, MWCO 10 kDa), suspended 
in PBS (for cell cultures) or water (for characterization) 
at 2 mg ml−1, and filtrated over 0.22 µm cellulose filters 
for sterilization. ζ-potential measurements are shown 
in Additional file  1: Table S1; UV–Vis and fluorescence 
spectra are shown in Additional file 1: Figures S1 and S2.
Control samples were prepared for all of the pep-
tide types and TAMRA using the same conditions with 
the exception of EDC and S-NHS, aiming to prove that 
unspecific absorption of the peptides on the NPs was 
avoided. Theses samples were cleaned as the activated 
samples and they were characterized by UV/Vis and fluo-
rescence spectroscopy, showing the absence of observ-
able unspecific absorption (i.e., lack of fluorescence).
Incubation of cells with nanoparticles
All the experiments were carried out under sterile con-
ditions working with microbiological class II safety cabi-
nets. The NPs were resuspended in  H2O, with a degree of 
purity milliQ and sterile, to obtain stock solutions at dif-
ferent concentrations. Special attention was paid to avoid 
turbidity in the solution and tips were always used with 
a filter to avoid possible cross contaminations. 500  µl 
aliquots were stored at 4 °C until the time of use. Work-
ing solutions of the NPs were made from stock solu-
tions in DMEM SC medium (10% Foetal bovine serum 
(FBS), 1% penicillin/streptomicyn (PS), 1% Glutamine 
(G)) and adjusted to 0.2 mg/ml (1.5 μM NPs). The maxi-
mum number of NPs used per cell was estimated to be 
2.7 × 109 NPs/cell, that is, 300 μl of a solution of 1.5 μM 
NPs that was added to  105 cells. In order to perform 
in vitro assays, Vero cells were cultured in 35 mm glass 
plates overnight. The cells were washed in DMEM SC 
(10% FBS, 1% PS, 1% G) and the existing medium was 
replaced by 300  ml of the solutions containing the NPs 
at optimal concentration of 1.5 μM. The NPs were incu-
bated in incubation chambers at 37 °C and 5% CO2 and 
observed with the confocal microscope. The incubation 
time periods ranged from 20 min to 3 h to observe differ-
ent degree of accumulation in the cells.
Plasmids and transfections
A vector encoding enhanced green fluorescent protein 
(EGFP)-LBR (Lamin B receptor) was kindly provided by 
Loren Fong from UCLA. Plasmid encoding EGFP-Lamin 
B1 was a generous gift of Howard Worman from Colum-
bia University New York. EGFP-tubulin and –actin, were 
from Clontech. A vector encoding B23 nucleolar pro-
tein was kindly provided by Carmen Rivas from Centro 
Nacional de Biotecnología, Madrid.
Transfections were performed by using the TransIT 
2020 Transfection Reagent from Mirus according to the 
manufacturer’s recommendations. Briefly, Vero cells 
were grown on 35  mm tissue culture plates, in DMEM 
(5% FBS, 1% PS, 1% G), until 80% confluence. Separately, 
50 µl of DMEM, serum- and antibiotics-free, was mixed 
with 0.5  µg of DNA and 1.3  µl of TransIT 2020. The 
mixture was incubated for 20 min at room temperature 
before addition to cells. To minimize cytotoxicity and 
increase the efficiency of the transfection, cells medium 
was replaced by 300  µl of fresh DMEM 5% serum and 
antibiotics-free before adding the DNA-TransIT mixture. 
Similarly, after 4 h, the transfection mixture was removed 
from cells and 500 µl of fresh medium (5% FBS, 1% PS, 
1% G) was added. At 24  h after transfection, cells were 
incubated with the NPs as explained below and analyzed 
by confocal microscopy.
Inhibition assays
Nocodazole was used at concentration of 2.5  µM and 
actin depolymerizing Latrunculin A at 0.1  µM. We first 
ensured that cytotoxicity, determined by the trypan blue 
exclusion method, did not exceed 10% of cell death after 
drug incubation at the indicated working concentra-
tions. Cells were pretreated for 30 min with inhibitors at 
the indicated working concentrations in growth medium 
for 30  min at 37  °C, further incubated with 1.5  µM of 
NPs for 30 min at 37 °C and then imaged. After 2 h, cul-
ture medium was replaced and washed for 1 h and then 
imaged.
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Cell viability and proliferation assays
To evaluate cell viability after incubation with peptides 
and NPs, Vero cells seeded in 24 well plates were incu-
bated in DMEM containing delivery DBP or negative 
control IntCt at concentrations ranging from 0 to 100 µM 
of each peptide. For NPs the concentrations were rang-
ing from 0 to 1 mg/ml (1–7.5 µM NPs). After incubation 
with peptides or nanoparticles for 24  h, cells were har-
vested and the number of viable cells present in the cell 
suspensions was determined by Tripan blue dye exclu-
sion assay (Sigma). Briefly, 20 µl of PBS with Tripan Blue 
0.08% (w/v) were added to equal volume of cell suspen-
sion and mixed. After 2 min, blue cells (dead cells) were 
counted using a hematocytometer and a conventional 
light microscope.
To evaluate cell proliferation 3 × 104 Vero cells/well 
seeded in 96 well plates were incubated in 50 µl DMEM 
containing DBPs and negative control or NPs at the range 
of concentrations previously used in the cell viability 
assays. After 24 h incubation, cell proliferation was deter-
mined using CellTiter 96 Aqueous™ (Promega) assay, fol-
lowing manufacturer´s indications.
Flow cytometry
Vero cells seeded in 24-well plates were incubated for 
120  min at 37  °C with Au@DBPs at several concentra-
tions. Then, cells were washed with PBS, harvested by 
trypsinization and washed again with flow cytometry 
buffer (PBS, 0.01% sodium azide and 0.1% bovine serum 
albumin). In order to determine the fluorescence inten-
sity per dose, 10,000 cells/per each Au@DBPs concentra-
tion were scored and analysed in a FACS Canto II flow 
cytometer (BD Sciences).
Time‑lapse video microscopy
Confocal microscopy was carried out using a Leica TCS 
SPE confocal microscope that included a humidified 
incubation chamber, a  CO2 controller and a heating unit. 
Selected stacks were recorded every 10-s using the Leica 
Microsystems LAS AF program and the films were dis-
played at 1–5 frames/s.
Fluorescence quantification
To quantify the intracellular accumulation of different 
DBP, cytoplasmic and background regions were selected 
and mean fluorescence intensity (MFI) quantified. Final 
MFI was calculated as indicated (cytoplasmic region—
background). Quantitative analysis of MFI was per-
formed with the Leica LAS-AF imaging program. At least 
thirty cells from three independent experiments were 
examined for each formulation.
Data analysis
One-way analysis of variance was performed with the sta-
tistical package GraphPad InStat. Bonferroni’s correction 
was applied for multiple comparisons. Data were presented 
as mean standard deviations. Differences were considered 
statistically significant with a p value of 0.001 (α = 0.05).
Authors’ contributions
ID, PdP, JMF and CA designed the research plan and experiments. ID, PdP, BP, 
MAC‑G, IG and MM carried out the experiments. ID, PdP, JMF and CA wrote the 
manuscript. All authors read and approved the final manuscript.
Author details
1 Dpt. Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y 
Alimentaria (INIA), Carretera de la Coruña km 7.5, 28040 Madrid, Spain. 2 Insti‑
tuto de Nanociencia de Aragón, Universidad de Zaragoza, Mariano Esquillor, 
s/n, 50018 Zaragoza, Spain. 3 Centro Singular de Investigación en Química 
Biolóxica e Materiais Moleculares (CiQUS), Departamento de Física de Partícu‑
las, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, 
Spain. 4 Aragon Materials Science Institute (ICMA), CSIC‑University of Zaragoza 
and CIBER‑BBN, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain. 
Additional files
Additional file 1:  Figure S1. UV/Vis spectra of “bare” NPs (Au@tiopronin) 
before the modification, and peptide, PEG or TAMRA‑CAD modified NPs. a) 
DBP (red line, Au@tiopronin‑DynPro), IntCT (cyan line, Au@tiopronin‑IntCt) 
and TAMRA (blue line, Au@tiopronin‑IntCt‑TAMRA‑CAD); b) DBP‑PEG (red 
line, Au@tiopronin‑DynPro/PEG), IntCT‑PEG (cyan line, Au@tiopronin‑
IntCt/PEG) and TAMRA‑PEG (blue line, Au@tiopronin‑IntCt‑TAMRA‑CAD/
PEG). Figure S2. Fluorescence spectra of “bare” NPs (Au@tiopronin) before 
the modification, and peptide, PEG or TAMRA‑CAD modified NPs. a) DBP 
(red line, Au@tiopronin‑DynPro), IntCT (cyan line, Au@tiopronin‑IntCt) and 
TAMRA (blue line, Au@tiopronin‑IntCt‑TAMRA‑CAD); b) DBP‑PEG (red line, 
Au@tiopronin‑DynPro/PEG), IntCT‑PEG (cyan line, Au@tiopronin‑IntCt/
PEG) and TAMRA‑PEG (blue line, Au@tiopronin‑IntCt‑TAMRA‑CAD/PEG). 
Figure S3. ζ‑potential bar diagram of “bare” NPs (Au@tiopronin) before 
the modification, and modified peptide or TAMRA‑CAD modified NPs: DBP 
(Au@DynPro), IntCT (Au@IntCt), TAMRA (Au@TAMRA‑CAD), DBP‑PEG (Au@
DynPro/PEG), IntCT‑PEG (Au@IntCt/PEG) and TAMRA‑PEG (Au@TAMRA‑
CAD/PEG). Table S1. ζ‑potential values of “bare” NPs (Au@tiopronin) 
before the modification, and peptide, PEG or TAMRA‑CAD modified 
NPs: DBP (Au@DynPro), IntCT (Au@IntCt), TAMRA (Au@TAMRA‑CAD), 
DBP‑PEG (Au@DynPro/PEG), IntCT‑PEG (Au@IntCt/PEG) and TAMRA‑PEG 
(Au@TAMRA‑CAD/PEG). Figure S4. The figure shows the cellular uptake 
(according to intracellular MFI) of Au@DynPro, Au@DynPro‑PEG, com‑
pared to nanoparticles modified with internal control peptide (IntCt), Au@
IntCt and Au@IntCt‑PEG. Mean fluorescence intensity (MFI) of modified 
NPs after 1 h incubation. Figure S5. This figure shows the absence of 
cytotoxic effect of the NPs in Vero cells. Cell viability (a) and cell prolifera‑
tion (b) were analyzed after incubation of cells with increasing concentra‑
tions of the different Au@DBP that exceeded those used in this study. A 
significant decrease in cell counts or cell proliferation was not observed.
Additional file 2: Movie 1. Motion beyond cell boundaries. This movie 
shows a general view of Au@DBP motion and dispersion in 293T cells 
incubated with 0.2 mg/ml of Au@DynPro during 1.5 h. Au@DBP displayed 
short and long tracks of bidirectional motion along a cell projection con‑
necting a neighboring cell. Movement results in transfer of Au@DynPro to 
the latter. The time lapse covers about 7 min at a rate of 5 frames/s.
Additional file 3: Movie 2. Intracellular movement of NPs linear trajecto‑
ries. This movie displays a Vero cell incubated with Au@DynPro at 0.2 mg/
ml during 1.5 h showing linear and stable tracks of directed motion in the 
perinuclear area. The time lapse covers 40 s at a rate of 3 frames/s.
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